SQZ SQZ Biotechnologies Company

SQZ Biotech is a clinical-stage biotechnology company developing transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Using our proprietary technology, we have the unique ability to engineer almost any cell type and deliver multiple materials, potentially resulting in powerful, multifunctional cell therapies for a range of diseases. We are creating cell therapies that we believe will be well-tolerated and able to provide therapeutic benefit for patients and potentially improve the patient experience, with accelerated production timelines under 24 hours and the elimination of difficult pre-conditioning and lengthy hospital stays.

$13.16  +1.16 (9.67%)
As of 11/30/2021 16:00:02 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  10/29/2020
Outstanding shares:  28,066,795
Average volume:  55,843
Market cap:   $344,660,243
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    78472W104
ISIN:        US78472W1045
Sedol:      BMGW906
Valuation   (See tab for details)
PE ratio:   -4.52
PB ratio:   2.53
PS ratio:   20.00
Return on equity:   -55.94%
Net income %:   -432.38%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy